1,303 results match your criteria Hurthle Cell Carcinoma

Development and validation of a prognostic nomogram for Hürthle cell thyroid carcinoma: a SEER-based study.

Gland Surg 2022 Mar;11(3):535-544

Department of General Surgery, Xiangya Hospital, Central South University, Changsha, China.

Background: Hürthle cell carcinoma is a rare subtype of thyroid cancer, and its clinical behavior and biological characteristics remain unclear. This study aimed to establish nomogram models for the prognostic evaluation of Hürthle cell thyroid carcinoma (HCTC) in terms of both cancer-specific survival (CSS) and overall survival (OS).

Methods: Data for a total of 3,264 patients with HCTC (2004 to 2018) were extracted from the Surveillance, Epidemiology, and End Results (SEER) database. Read More

View Article and Full-Text PDF

Late renal toxicity in patient with radioiodine-refractory differentiated thyroid cancer treated with lenvatinib: A case report and literature review.

J Oncol Pharm Pract 2022 Apr 4:10781552221092329. Epub 2022 Apr 4.

Hematology/Oncology Department, 23335Loma Linda University Medical Center, Loma Linda, California, United States.

Introduction: Thyroid carcinoma is the most common endocrine neoplasm. Multimodal therapy including surgery, radioactive iodine (RAI) therapy, and indefinite suppression of thyroid-stimulating hormone has led to an 85% cure rate in differentiated thyroid tumors (DTT). Approximately 5-10% of patients will have recurrence or metastases that have the potential to become resistant to RAI treatment. Read More

View Article and Full-Text PDF

Extracolonic tumours in a pedigree with EPCAM-related Lynch Syndrome.

Eur J Med Genet 2022 May 31;65(5):104479. Epub 2022 Mar 31.

Gastroenterology, Centro Hospitalar Universitário do Porto, Porto, Portugal; Institute for Research Innovation in Health (i3S), University of Porto, Porto, Portugal. Electronic address:

Lynch Syndrome is characterized by phenotypic and genotypic heterogeneity. Despite scarce evidence, individuals with an EPCAM deletion appear to have a comparable risk of colorectal cancer (CRC) as MSH2 mutation carriers, but a lower risk of extracolonic cancer (such as endometrial cancer) unless the deletion extends close to the promoter of MSH2. A genotype-phenotype correlation is yet to be established for EPCAM alterations. Read More

View Article and Full-Text PDF

TROP2: a potential marker in diagnosis of thyroid neoplasms.

Ir J Med Sci 2022 Mar 30. Epub 2022 Mar 30.

Department of Pathology, Gaziantep University Medical Faculty Hospital, Gaziantep, Turkey.

Background And Objectives: The human trophoblast cell surface antigen (TROP-2), a transmembrane glycoprotein, has recently been investigated as a valuable marker of thyroid epithelial neoplasms. In this study, we aimed to demonstrate the diagnostic utility of TROP2 in thyroid neoplasms.

Methods: A total of 308 cases, including 170 cases of different PTC variants, 50 cases of benign and non-neoplastic lesions, and 86 cases of other neoplasms (NIFT-P, poorly differentiated thyroid carcinoma, anaplastic thyroid carcinoma, follicular thyroid carcinoma, Hürthle cell carcinoma, and medullary thyroid carcinoma), were included in this study. Read More

View Article and Full-Text PDF

Clinicopathological indicators for TERT promoter mutation in papillary thyroid carcinoma.

Clin Endocrinol (Oxf) 2022 Mar 28. Epub 2022 Mar 28.

Department of Pathology, Seoul National University Bundang Hospital, Seongnam, Korea.

Objective: Mutations in the telomerase reverse transcriptase (TERT) promoter have been reported as a convincing prognostic factor in papillary thyroid carcinomas (PTCs). We aimed to investigate the frequency of TERT promoter mutations in patients with thyroid cancer and identify the clinicopathological factors associated with them in PTCs.

Design: A total of 1086 consecutive cases of thyroid cancer composed of mostly PTCs were included in this study. Read More

View Article and Full-Text PDF

Overview of the 2022 WHO Classification of Thyroid Neoplasms.

Endocr Pathol 2022 Mar 14;33(1):27-63. Epub 2022 Mar 14.

Department of Pathology, University Health Network, University of Toronto, Toronto, ON, Canada.

This review summarizes the changes in the 5th edition of the WHO Classification of Endocrine and Neuroendocrine Tumors that relate to the thyroid gland. The new classification has divided thyroid tumors into several new categories that allow for a clearer understanding of the cell of origin, pathologic features (cytopathology and histopathology), molecular classification, and biological behavior. Follicular cell-derived tumors constitute the majority of thyroid neoplasms. Read More

View Article and Full-Text PDF

Subcutaneous implantation of oncocytic thyroid cell aggregates nine years later from thyroidectomy. A case report.

Int J Surg Case Rep 2022 Apr 10;93:106935. Epub 2022 Mar 10.

Division of Surgery, Istituto Auxologico Italiano IRCCS, Piazzale Brescia, 20, 20149 Milan, Italy; Department of Pathophysiology and Transplantation, University of Milan, 20122 Milan, Italy.

Introduction And Importance: Subcutaneous implantation of thyroid tissue is a rare clinical condition that involves the head and neck region and occurs after surgery, diagnostic procedures or cervical trauma.

Case Presentation: A 90-year old woman with two skin nodules on her thyroidectomy scar was hospitalized and treated by two surgical excisions. Histologically, these lesions were two aggregates of cutaneous oncocytic thyroid cells. Read More

View Article and Full-Text PDF

Immune characterization of thyroid neoplasm's and its variants using immunohistochemical markers: CK-19, Galectin-3 and Hector Battifora mesothelial-1.

Ann Diagn Pathol 2022 Jun 2;58:151931. Epub 2022 Mar 2.

Department of Pathology, Kalinga Institute of Medical Sciences, Patia, Bhubaneswar, India.

Background: Nodular lesions of the thyroid are amongst the common palpable lesions that are encountered by the pathologists in the fine needle aspiration clinics and not only aspiration smears, but even biopsy sections pose significant challenges in their characterization and further classification. Neoplastic lesions of the thyroid have shown a steady rise worldwide and are diagnosed at age younger than most other cancers. Histopathology remains the gold standard in diagnosis and classification of thyroid neoplasms, with variable sensitivity and specificity of immunohistochemical markers, also attributed to variation in the inclusion criteria. Read More

View Article and Full-Text PDF

Ga-DOTATATE PET/CT versus In-octreotide scintigraphy in patients with neuroendocrine tumors: a prospective study.

Radiol Bras 2022 Jan-Feb;55(1):13-18

A.C. Camargo Cancer Center - Imaging Department, São Paulo, SP, Brazil.

Objective: To compare Ga-DOTA-DPhe1,Tyr3-octreotate (Ga-DOTATATE) positron-emission tomography/computed tomography (PET/CT) findings with those of conventional In-octreotide scintigraphy in patients with neuroendocrine tumors (NETs).

Materials And Methods: This was a single-center prospective study including 41 patients (25 males; mean age, 55.4 years) with biopsy-proven NETs who underwent whole-body In-octreotide scintigraphy and whole-body Ga-DOTATATE PET/CT. Read More

View Article and Full-Text PDF
February 2021

Clinical outcomes of a cohort of 271 patients with lung metastases from differentiated thyroid carcinoma.

Clin Endocrinol (Oxf) 2022 Feb 22. Epub 2022 Feb 22.

Endocrinology Department, Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisboa, Portugal.

Context: Lung is the most common site of distant metastases from differentiated thyroid carcinoma (DTC).

Objective: To investigate the outcomes of a cohort of patients with DTC and lung metastases (LM).

Methods: A retrospective analysis of a cohort of 271 patients with LM was performed. Read More

View Article and Full-Text PDF
February 2022

Quantitative classification and radiomics of [F]FDG-PET/CT in indeterminate thyroid nodules.

Eur J Nucl Med Mol Imaging 2022 Feb 9. Epub 2022 Feb 9.

Department of Radiology, Section of Nuclear Medicine, Leiden University Medical Center, Leiden, the Netherlands.

Purpose: To evaluate whether quantitative [F]FDG-PET/CT assessment, including radiomic analysis of [F]FDG-positive thyroid nodules, improved the preoperative differentiation of indeterminate thyroid nodules of non-Hürthle cell and Hürthle cell cytology.

Methods: Prospectively included patients with a Bethesda III or IV thyroid nodule underwent [F]FDG-PET/CT imaging. Receiver operating characteristic (ROC) curve analysis was performed for standardised uptake values (SUV) and SUV-ratios, including assessment of SUV cut-offs at which a malignant/borderline neoplasm was reliably ruled out (≥ 95% sensitivity). Read More

View Article and Full-Text PDF
February 2022

Primary intraosseous oncocytic mucoepidermoid carcinoma of the jaw: First case report.

Oral Oncol 2022 03 26;126:105732. Epub 2022 Jan 26.

Department of Oral Pathology and Microbiology, Centre for Dental Education and Research, All India Institute of Medical Sciences, New Delhi, India. Electronic address:

View Article and Full-Text PDF

Follicular and Hurthle Cell Carcinoma: Comparison of Clinicopathological Features and Clinical Outcomes.

Thyroid 2022 03;32(3):245-254

Head and Neck Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA.

Follicular thyroid carcinoma (FTC) and Hurthle cell carcinoma (HCC) are rare and aggressive thyroid cancers with limited published data comparing their outcomes or regarding their subtypes. The aim of this study was to describe clinicopathological features and compare clinical outcomes of patients with FTC and HCC based on the 2017 World Health Organization definition and extent of vascular invasion (VI). We retrospectively studied 190 patients with HCC and FTC primarily treated with surgery at Memorial Sloan Kettering Cancer Center between 1986 and 2015. Read More

View Article and Full-Text PDF

The differences in distant metastatic patterns and their corresponding survival between thyroid cancer subtypes.

Head Neck 2022 04 25;44(4):926-932. Epub 2022 Jan 25.

Department of Pathology, Cancer Genome Center and Thyroid Disease Center, Izumi City General Hospital, Izumi, Japan.

Introduction: This study aimed to systematically elucidate the metastatic patterns and their corresponding survival of each thyroid cancer subtype at time of diagnosis.

Methods: We accessed the Surveillance, Epidemiology, and End Results (SEER) database from 2010 to 2018 to search for primary thyroid cancers with DM at presentation (M1).

Results: We included 2787 M1 thyroid cancers for statistical analyses and the incidence of DM at presentation was 2. Read More

View Article and Full-Text PDF

[Rapid diagnosis for liquid-based fine needle aspiration of thyroid nodules].

Ann Pathol 2022 Jan 12. Epub 2022 Jan 12.

Service d'anatomie et cytologie pathologiques, hôpital Lyon Sud, hospices civils de Lyon, Pierre-Bénite, France; Université Lyon-1, EA 3738 CICLY, 69921 Oullins cedex, France. Electronic address:

Introduction: The discovery of thyroid nodule can be a source of concern for the patient. Fine-needle aspiration is the gold standard for their evaluation. We establish a new rapid diagnosis procedure for liquid-based fine needle aspiration (LB-FNA) of thyroid nodules. Read More

View Article and Full-Text PDF
January 2022

[F]FDG-PET/CT to prevent futile surgery in indeterminate thyroid nodules: a blinded, randomised controlled multicentre trial.

Eur J Nucl Med Mol Imaging 2022 05 4;49(6):1970-1984. Epub 2022 Jan 4.

Department of Radiology, Section of Nuclear Medicine, Leiden University Medical Center, Leiden, the Netherlands.

Purpose: To assess the impact of an [F]FDG-PET/CT-driven diagnostic workup to rule out malignancy, avoid futile diagnostic surgeries, and improve patient outcomes in thyroid nodules with indeterminate cytology.

Methods: In this double-blinded, randomised controlled multicentre trial, 132 adult euthyroid patients with scheduled diagnostic surgery for a Bethesda III or IV thyroid nodule underwent [F]FDG-PET/CT and were randomised to an [F]FDG-PET/CT-driven or diagnostic surgery group. In the [F]FDG-PET/CT-driven group, management was based on the [F]FDG-PET/CT result: when the index nodule was visually [F]FDG-positive, diagnostic surgery was advised; when [F]FDG-negative, active surveillance was recommended. Read More

View Article and Full-Text PDF

Oncocytic Papillary Thyroid Carcinoma and Oncocytic Poorly Differentiated Thyroid Carcinoma: Clinical Features, Uptake, and Response to Radioactive Iodine Therapy, and Outcome.

Front Endocrinol (Lausanne) 2021 16;12:795184. Epub 2021 Dec 16.

Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada.

Objective: The main objective of this study was to review the clinicopathologic characteristics and outcome of patients with oncocytic papillary thyroid carcinoma (PTC) and oncocytic poorly differentiated thyroid carcinoma (PDTC). The secondary objective was to evaluate the prevalence and outcomes of RAI use in this population.

Methods: Patients with oncocytic PTC and PDTC who were treated at a quaternary cancer centre between 2002 and 2017 were retrospectively identified from an institutional database. Read More

View Article and Full-Text PDF
February 2022

Using Deep Convolutional Neural Networks for Enhanced Ultrasonographic Image Diagnosis of Differentiated Thyroid Cancer.

Biomedicines 2021 Nov 26;9(12). Epub 2021 Nov 26.

Professional Master Program in Artificial Intelligence in Medicine, College of Medicine, Taipei Medical University, Taipei 10675, Taiwan.

Differentiated thyroid cancer (DTC) from follicular epithelial cells is the most common form of thyroid cancer. Beyond the common papillary thyroid carcinoma (PTC), there are a number of rare but difficult-to-diagnose pathological classifications, such as follicular thyroid carcinoma (FTC). We employed deep convolutional neural networks (CNNs) to facilitate the clinical diagnosis of differentiated thyroid cancers. Read More

View Article and Full-Text PDF
November 2021

Anti-PD-1 Immunotherapy Combined With Stereotactic Body Radiation Therapy and GM-CSF as Salvage Therapy in a PD-L1-Positive Patient With Refractory Metastatic Thyroid Hürthle Cell Carcinoma: A Case Report and Literature Review.

Front Oncol 2021 23;11:782646. Epub 2021 Nov 23.

Cancer Center, Renmin Hospital of Wuhan University, Wuhan, China.

Thyroid Hürthle cell carcinoma, known as thyroid eosinophilic carcinoma, is a rare pathological type of differentiated thyroid cancer (DTC), representing 3-4% of all thyroid cancers. However, given the high risk of invasion and metastasis, thyroid Hürthle cell carcinoma has a relatively poor prognosis. Traditional treatment methods have limited effects on patients with metastatic thyroid cancers. Read More

View Article and Full-Text PDF
November 2021

Targeting the mTOR Pathway in Hurthle Cell Carcinoma Results in Potent Antitumor Activity.

Mol Cancer Ther 2022 02 17;21(2):382-394. Epub 2021 Nov 17.

Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.

Hurthle cell carcinomas (HCCs) are refractory to radioactive iodine and unresponsive to chemotherapeutic agents, with a fatality rate that is the highest among all types of thyroid cancer after anaplastic thyroid cancer. Our previous study on the genomic landscape of HCCs identified a high incidence of disruptions of mTOR pathway effectors. Here, we report a detailed analysis of mTOR signaling in cell line and patient-derived xenograft mouse models of HCCs. Read More

View Article and Full-Text PDF
February 2022

Clinicopathological Characteristics and Disease-Free Survival in Patients with Hürthle Cell Carcinoma: A Multicenter Cohort Study in South Korea.

Endocrinol Metab (Seoul) 2021 10 28;36(5):1078-1085. Epub 2021 Oct 28.

Division of Endocrinology and Metabolism, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.

Background: Hürthle cell carcinoma (HCC), a type of thyroid carcinoma, is rare in South Korea, and few studies have investigated its prognosis.

Methods: This long-term multicenter retrospective cohort study evaluated the clinicopathological features and clinical outcomes in patients with HCC who underwent thyroid surgery between 1996 and 2009.

Results: The mean age of the 97 patients included in the study was 50. Read More

View Article and Full-Text PDF
October 2021

Patient Eligibility for Transoral Endoscopic Thyroidectomy Vestibular Approach in an Endemic Region.

Sisli Etfal Hastan Tip Bul 2021 24;55(3):304-309. Epub 2021 Sep 24.

Department of General Surgery, Division of Endocrine Surgery, Ege University School of Medicine, Izmir, Turkey.

Objective: Transoral endoscopic thyroidectomy vestibular approach (TOETVA) is a scarless method that enables thyroidectomyusing natural orifice of the body. The opinion which is even common among TOETVA performing surgeons is that this surgery involves a small percentage of thyroidectomy applied patients. In this study, based on the currently accepted exclusion criteria, we aimed to determine what percentage of patients, who underwent thyroidectomy in an endemic area are actually suitable for TOETVA. Read More

View Article and Full-Text PDF
September 2021

Molecular Signature Expands the Landscape of Driver Negative Thyroid Cancers.

Cancers (Basel) 2021 Oct 15;13(20). Epub 2021 Oct 15.

Genetic Bases of Thyroid Tumors Laboratory, Division of Genetics, Department of Morphology and Genetics, Escola Paulista de Medicina, Universidade Federal de São Paulo, Pedro de Toledo 669, 11 Andar, São Paulo 04039-032, SP, Brazil.

Thyroid cancer is the most common endocrine malignancy. However, the cytological diagnosis of follicular thyroid carcinoma (FTC), Hürthle cell carcinoma (HCC), and follicular variant of papillary thyroid carcinoma (FVPTC) and their benign counterparts is a challenge for preoperative diagnosis. Nearly 20-30% of biopsied thyroid nodules are classified as having indeterminate risk of malignancy and incur costs to the health care system. Read More

View Article and Full-Text PDF
October 2021

Expanding the spectrum of thyroid carcinoma with somatic DICER1 mutation: a survey of 829 thyroid carcinomas using MSK-IMPACT next-generation sequencing platform.

Virchows Arch 2022 Feb 27;480(2):293-302. Epub 2021 Sep 27.

Department of Pathology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA.

DICER1 gene encodes an RNaseIII endoribonuclease essential for the cleavage of pre-microRNA to mature microRNA. Germline DICER1 mutation results in DICER syndrome, a cancer predisposition syndrome which manifests in the thyroid gland as early-onset multinodular goiter and increased risk for differentiated thyroid carcinoma. Recently, somatic DICER1 mutations were described in various thyroid neoplasms, including follicular adenoma, papillary thyroid carcinoma, follicular carcinoma, and poorly differentiated thyroid carcinoma. Read More

View Article and Full-Text PDF
February 2022

Suspicious thyroid nodules 4 cm require a diagnostic lobectomy regardless of their benign fine needle aspiration results.

Asian J Surg 2022 May 9;45(5):1113-1116. Epub 2021 Sep 9.

Department of Surgery, CHA Ilsan Medical Center, Goyang-si, Republic of Korea.

Background/objective: The diagnostic accuracy of fine needle aspiration biopsy (FNAB) seems limited in large thyroid nodules with Bethesda Cat. 2 result. We aimed to determine the incidence of carcinoma with benign cytology and the reason for the high false-positive rate in thyroid nodules ≥4 cm. Read More

View Article and Full-Text PDF

Thyroid hemiagenesis associated with Hurthle cell carcinoma: A case report.

Int J Surg Case Rep 2021 Sep 7;86:106372. Epub 2021 Sep 7.

Surgical Oncology Division, Department of Surgery, Dr. Cipto Mangunkusumo General Hospital, Faculty of Medicine, Universitas Indonesia, Indonesia.

Introduction And Importance: Thyroid hemiagenesis (TH) is a rare congenital anomaly where one lobe fails to develop, especially more frequently occurs on the left lobe. The exact mechanisms for thyroid morphogenesis remain unclear. In this paper, we report a rare case of right lobe TH associated with Hurthle cell carcinoma. Read More

View Article and Full-Text PDF
September 2021

Clavicular Metastasis as an Initial Presentation of Papillary Thyroid Cancer.

Case Rep Endocrinol 2021 26;2021:6662071. Epub 2021 Aug 26.

Division of Endocrinology, University of Florida College of Medicine-Jacksonville, Jacksonville, FL, USA.

Objective: We present the case of a 44-year-old man with a large neck mass to highlight the unique presentation of papillary thyroid carcinoma (PTC) metastatic to the clavicle.

Methods: We reviewed the medical record for a detailed history and physical examination findings. Our radiology colleagues examined the diagnostic imaging studies performed. Read More

View Article and Full-Text PDF

Synchronous occurrence of Hurthle cell carcinoma with Hodgkin's lymphoma; the first reported case with literature review.

Ann Med Surg (Lond) 2021 Sep 24;69:102750. Epub 2021 Aug 24.

Smart Health Tower, Madam Mitterrand Street, Sulaimani, Kurdistan, Iraq.

Introduction: Hurthle cell carcinoma (HCC) is a rare type of thyroid cancer while Hodgkin's lymphoma (HL) is an uncommon cancer of the lymphocytes. The synchronous occurrence of HCC and HL in a single person has not been described in the literature. This report aims to present the first case of synchronous HCC and HL. Read More

View Article and Full-Text PDF
September 2021

Thyroid Nodule Size as a Predictor of Malignancy in Follicular and Hurthle Neoplasms.

Asian Pac J Cancer Prev 2021 Aug 1;22(8):2597-2602. Epub 2021 Aug 1.

Radiology Informatics Lab, Department of Radiology, Mayo Clinic, Rochester, MN, USA.

Introduction: The management of follicular (FN) and Hurthle cell neoplasms (HCN) is often difficult because of the uncertainty of malignancy risk. We aimed to assess characteristics of benign and malignant follicular and Hurthle neoplasms based on their shape and size.

Materials And Methods: Patients with Follicular adenoma (FA) or carcinoma (FC) and Hurthle Cell adenoma (HCA) or carcinoma (HCC) who had preoperative ultrasonography were included. Read More

View Article and Full-Text PDF